智通财经APP讯，安必平(688393.SH)披露2025年度业绩快报，2025年度实现营业总收入3.47亿元，同比 下降26.24%;归属于母公司所有者的净利润亏损4497.17万元，同比由盈转亏。 报告期内，国家集采政策全面落地实施，公司HPV产品线售价同比大幅下降，导致该业务收入减少约 4,650万元。报告期内，公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规 模。此外，为加速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，产品销售单价同比下 降，短期内对整体毛利产生一定影响。 ...

报告期内，国家集采政策全面落地实施，公司HPV产品线售价同比大幅下降，导致该业务收入减少约 4,650万元。报告期内，公司主动优化业务结构，聚焦主营业务收入拓展，相应减少代理产品业务规 模。此外，为加速市场渗透，公司积极推进渠道策略调整，扩大经销渠道比重，产品销售单价同比下 降，短期内对整体毛利产生一定影响。 安必平(688393.SH)披露2025年度业绩快报，2025年度实现营业总收入3.47亿元，同比下降26.24%;归属 于母公司所有者的净利润亏损4497.17万元，同比由盈转亏。 ...

安必平发布业绩快报，2025年度实现营业总收入3.47亿元，同比下降26.24%；净利润亏损4497.17万 元，上年同期净利润为2129.13万元。报告期内，国家集采政策全面落地实施，公司HPV产品线售价同 比大幅下降，导致该业务收入减少约4650万元。 ...

Core Viewpoint - Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. is expected to report a significant net loss for the fiscal year 2025, with projections indicating a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% compared to the previous year [3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to the parent company is projected to be between -52 million to -42 million yuan, a decrease of 73.29 million to 63.29 million yuan compared to the previous year [3]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -72 million to -62 million yuan, a decrease of 86.25 million to 76.25 million yuan compared to the previous year [3]. Group 2: Previous Year Performance - In the previous year, the total profit was 9.43 million yuan, with a net profit attributable to the parent company of 21.29 million yuan [5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 14.25 million yuan [5]. - The earnings per share for the previous year was 0.23 yuan [6]. Group 3: Reasons for Performance Change - The company's operating income has declined, primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of HPV product lines, leading to a revenue decrease of approximately 46.5 million yuan [7]. - The gross profit margin for the HPV product line has also been under pressure, resulting in a gross profit decrease of about 46 million yuan [7]. - The company is actively optimizing its business structure and focusing on expanding its main business revenue while reducing the scale of agency product business [7]. - To build long-term competitive advantages, the company is increasing its investment in product research and innovation, particularly in the fields of pathological intelligence and tumor companion diagnostics, which has led to an increase in operating costs [7]. - The company has made provisions for asset impairment in accordance with accounting standards and policies [7]. Group 4: Non-Operating Gains and Losses - The increase in non-recurring gains and losses is mainly due to increased investment income from associated companies [9].

Core Viewpoint - Anbiping (688393.SH) is expected to report significant losses in 2025, with net profit attributable to shareholders projected to be between -52 million to -42 million yuan, marking a substantial decline compared to the previous year [1][2] Group 1: Financial Performance - The company anticipates a net profit loss of -52 million to -42 million yuan for 2025, a decrease of 73.29 million to 63.29 million yuan year-on-year, representing a decline of 344.23% to 297.26% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -72 million to -62 million yuan, down by 86.25 million to 76.25 million yuan compared to the previous year, indicating a decrease of 605.13% to 534.97% [1] Group 2: Revenue and Business Impact - The company's operating revenue has declined year-on-year, primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of HPV products, leading to a revenue decrease of approximately 46.5 million yuan [2] - The gross profit margin for the HPV product line has also been under pressure, with gross profit decreasing by about 46 million yuan year-on-year [2] - The company is actively optimizing its business structure by focusing on core business revenue expansion and reducing the scale of agency product operations [2] Group 3: Strategic Initiatives - To adapt to market changes and build long-term competitive advantages, the company is enhancing its product research and development efforts, particularly in the fields of pathological intelligence and tumor companion diagnostics [2] - Although this strategy has led to an increase in operating costs in the current period, it is expected to lay a solid foundation for the company's sustainable development in the future [2]

Group 1 - The company Anbiping expects a net loss attributable to shareholders of the parent company for 2025, ranging from -52 million to -42 million yuan, representing a year-on-year decline of 344.23% to 297.26% [1] - The primary reason for the performance change is the impact of the main business, with a significant decrease in operating income and net profit due to the implementation of national centralized procurement policies [1] - The company's HPV product line experienced a notable price drop, leading to a revenue decrease of approximately 46.5 million yuan and a corresponding decline in gross profit margin [1] Group 2 - The company is actively optimizing its business structure by focusing on expanding its main business revenue and reducing the scale of agency product business [1] - To enhance market penetration, the company is adjusting its channel strategy to increase the proportion of distribution channels, which may temporarily affect overall gross profit but improves customer coverage efficiency [1] - The company is strengthening its product research and innovation efforts, particularly in the fields of digital pathology and tumor companion diagnostics, which has led to an increase in operating costs but lays a solid foundation for sustainable future development [1]

Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% [1] Financial Performance - The expected non-recurring net profit is projected to be between -72 million to -62 million yuan, indicating a year-on-year decrease of 605.13% to 534.97% [1] - The decline in revenue and gross profit from the HPV product line is estimated to be approximately 46.5 million yuan and 46 million yuan, respectively [1] Operational Factors - The decrease in financial performance is attributed to the national centralized procurement policy affecting the HPV product line [1] - Business structure optimization and channel strategy adjustments have negatively impacted the current gross profit [1] - Increased research and development investments have led to a rise in costs [1] - The company has made provisions for asset impairment [1] Non-Recurring Gains - There has been an increase in investment income from associated companies, contributing positively to non-recurring gains [1]

Group 1 - The core point of the news is that Nanjing Qianjing plans to reduce its stake in Anbiping by up to 1.61% of the total share capital due to funding needs, potentially cashing out approximately 45.81 million yuan at the current share price of 30.49 yuan per share [1][2] - Nanjing Qianjing currently holds 1.61% of Anbiping's shares, and if the reduction plan is fully implemented, it may lead to a complete exit from the company [2] - Anbiping has experienced a continuous decline in net profit for four consecutive years from 2021 to 2024, with gross profit margins decreasing from 77.92% to 67.23% during the same period [2] Group 2 - In the first three quarters of 2025, Anbiping reported revenue of approximately 253 million yuan, a year-on-year decrease of 28.29%, and a net profit attributable to shareholders of approximately -10.77 million yuan, a dramatic decline of 136.34% [2] - The primary reason for the decline in total profit is attributed to a significant reduction in gross profit from the HPV product line, which decreased by 41.05 million yuan, or 79.35% [2]